ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of response.

ABSTRACT:

Background

The combination of ISA101, a human papilloma virus (HPV) 16 peptide vaccine, and nivolumab showed a promising response rate of 33% in patients with incurable HPV-16⁺ cancer. Here we report long-term clinical outcomes and immune correlates of response.

Methods

Patients with advanced HPV-16⁺ cancer and less than two prior regimens for recurrence were enrolled to receive ISA101 (100 µg/peptide) on days 1, 22, and 50 and nivolumab 3 mg/kg every 2 weeks beginning day 8 for up to 1 year. Baseline tumor samples were stained with multiplex immunofluorescence for programmed death-ligand 1 (PD-L1), programmed cell death protein-1 (PD-1), CD3, CD8, CD68, and pan-cytokeratin in a single panel and scanned with the Vectra 3.0 multispectral microscope. Whol

SUBMITTER: Sousa LG 

PROVIDER: S-EPMC9066369 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature